FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback